Abstract
The effect of peroxisome proliferator‐activated receptor‐gamma (PPARγ) agonist rosiglitazone (RGZ), a thiazolidinedione (TZL), on cardiac ischemia/reperfusion (IR) injury is controversial. We tested effects of RGZ on post‐IR function and infarction in a consomic rat model that exhibits genetically determined cardioprotection. 15 min after 2 × 5‐min boluses of 50 μM RGZ or vehicle (Con), isolated hearts from Brown Norway (BN), Dahl Salt Sensitive (SS), and consomic (SS‐6BN) rats underwent 30 min global I and 120 min R. Systolic and developed left‐ventricular pressure (LVP), contractility, and coronary flow at 120 min R were decreased while diastolic LVP and infarct size increased in all Con groups, more so in SS than in BN or SS‐6BN hearts. RGZ enhanced IR injury more in SS‐6BN than in SS or BN hearts. Concurrent fluorescent redox state measurements suggested incomplete washout of RGZ and mitochondrial uncoupling before IR. These data confirm prior reports of deleterious effects of TZL on cardiac IR injury that appear to vary by species, dose, timing and route of administration, model used and PPARγ‐independent actions. These results also suggest genetic predisposition plays a role in the adverse response to TZLs. If translated clinically, PPARγ agonists may adversely enhance cardiac IR injury in genetically susceptible patients. Research supported by Department of Veterans Affairs (MR: CARA‐026–10F) and NIH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.